Akdes Serin Harmanci
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Dr. Akdes Serin Harmanci is an Assistant Professor at Baylor College of Medicine in the Department of Neurosurgery. He is based in the United States and focuses his research on glioblastoma, particularly the role of CXCR4 expression in the proneural-to-mesenchymal transition. His work contributes to the understanding of tumor biology and potential therapeutic targets in neurosurgery.
Articles (23)
Year:
2026
Diffuse midline gliomas (DMG) are aggressive pediatric brain tumors characterized by chromatin and transcriptional dysregulation induced by H3K27M mutations. Strategies for overcoming epigenetic dysfunction to reduce DMG tumorigenesis remain limited. We identified multiple components of the SAGA and ATAC chromatin regulatory complexes as DMG genetic dependencies and found that genetic or pharmacological inhibition of the SAGA/ATAC-associated chromatin reader SGF29 reduces DMG proliferation. Small molecules targeting SAGA/ATAC-associated histone acetylation, ubiquitination, and methylation similarly suppressed DMG growth. Further chromatin profiling and RNAseq analyses reveal that SGF29 controls H3K9ac and H3K4me3 dynamics at both H3K27M-bound and H3K27M-independent target genes linked to proliferation, differentiation, and metabolism. Finally, we find that SAGA/ATAC inhibition may reduce DMG viability by repressing cholesterol metabolism gene expression and show that combinations of cholesterol- and SAGA/ATAC-targeting drugs synergistically reduce DMG growth. These findings reveal a functional link between SAGA/ATAC-dependent chromatin modulation and both transcriptional and metabolic dysregulation underlying DMG malignancy.
Year:
2026
Neuronal cells exhibit distinct molecular, electrophysiological and morphological features, yet current technologies offer limited capacity to capture these jointly at high throughput. Here, we present PREPS (PRedicting ElectroPhysiology in Single-cell data), a computational approach that learns mappings from transcriptomes to electrophysiological features using coupled measurements of electrophysiology, transcriptome, and morphology by Patch-Sequencing (Patch-Seq). PREPS fine-tunes a transformer on >8 million brain cells to obtain contextual embeddings and attention-ranked gene lists, trains elastic-net models to predict electrophysiological features (e.g., resting potential, input resistance, action-potential metrics) from these embeddings, and assigns electrophysiology- and morphology-based cell-type labels (inhibitory, pyramidal, non-spiking, hybrid). We also introduce DEEPS (Deep ElEectrophysiology Pathway Scores), a weighted, attention-informed electrophysiology module-scoring scheme that quantifies synaptic and excitability programs. Applied to glioma single-cell datasets, PREPS identifies neuronal-like tumor subpopulations with concordant predicted electrophysiology, consistent with neuronal program adoption by glioma cells. Applied to the Allen Brain non-neuronal atlases, PREPS identifies rare neuronal-like cells within committed oligodendrocyte precursors (COP), OPCs, and astrocytes, with elevated ionotropic receptor, ion channel, and action-potential machinery scores. In summary, PREPS enables atlas-scale inference of electrophysiology from RNA alone, generating testable hypotheses on neuron-glia signaling in cancer and health. It also helps prioritize targets for validation and therapeutic repurposing.
Year:
2026
BACKGROUND AND OBJECTIVES: Meningiomas are the most common primary tumor of the brain and may elicit hyperostosis of the adjacent bone. Whether hyperostosis is related to reactive changes of the overlying bone or by invasion of the tumor itself is unclear. In this article, we characterize the clinical and molecular differences of meningiomas with hyperostosis from those without hyperostosis. METHODS: One hundred and eighty-one primary, nonsyndromic, nonradiation-induced meningiomas with DNA and RNA sequencing were included in a retrospective study. Preoperative MRI and computed tomography scans were reviewed by a fellowship-trained neuroradiologist to identify the presence of hyperostosis or bone invasion. Clinical, radiographic, and surgical data were gathered for each patient. Bulk RNA sequencing was performed, and data were analyzed for gene set enrichment analysis, gene ontologies, and differentially expressed genes along with chromosomal deletions and canonical mutations. RESULTS: Sixty-six (36.5%) meningiomas had radiographic evidence of hyperostosis compared with 115 (63.5%) without hyperostosis. Patients with hyperostosis had more severe presentation with increased rates of emergency department admissions ( P = .0320) and seizure presentation ( P = .0480). Hyperostotic tumors preferentially manifested in the olfactory groove location ( P = .004). Radiographically, tumors with hyperostosis had higher rates of edema ( P = .0280), midline shift ( P = .010), nonhomogeneous enhancement ( P = .001), T2 hyperechoic signal ( P = .001), and bone invasion ( P < .001). Patients with hyperostosis had increased estimated blood loss intraoperatively ( P = .006), longer time in the operating room ( P = .045), and higher rates of craniectomy and cranioplasty ( P < .001 and P = .001). Fifty-five percent of all upregulated differentially expressed genes in hyperostotic tumors are secreted, and many are related to skeletal system development ( BMP3 , RBP4, MATN4 , CILP2, and FGF7 ). CONCLUSION: In a retrospective study, meningiomas with hyperostosis are region-specific, are related to higher intraoperative complications, and present with distinct radiographic features. Transcriptional analysis revealed upregulation of secreted proteins that positively influence bone development and growth.
Year:
2025
Background The reactivation of neurodevelopmental programs in cancer highlights parallel biological processes that occur in both normal development and brain tumors. Achieving a deeper understanding of how dysregulated developmental factors play a role in the progression of brain tumors is therefore crucial for identifying potential targets for therapeutic interventions. Single-cell RNA-sequencing (scRNA-Seq) provides an opportunity to understand how developmental programs are dysregulated and reinitiated in brain tumors at single-cell resolution. The aim of this study is to identify the developmental origins of brain tumors using scRNA-Seq data. Methods Here, we introduce COORS (Cell Of ORigin like CellS), a computational tool trained on developmental human brain single-cell datasets that annotates “developmental-like” cell states in brain tumors. COORS leverages cell type-specific multilayer perceptron models and incorporates a developmental cell type tree that reflects hierarchical relationships and models cell type probabilities. Results Applying COORS to various brain cancer datasets, including medulloblastoma (MB), glioma, and diffuse midline glioma (DMG), we identified developmental-like cells that represent putative cells of origin in these tumors. Our method provides both cell of origin classification and cell age regression, offering insights into the developmental cell types of tumor subgroups. COORS identified outer radial glia developmental cells within IDHWT glioma cells whereas oligodendrocyte precursor cells (OPCs) and neuronal-like cells in IDHMut. Interestingly, IDHMut subgroup cells that map to OPC show bimodal distributions that are both early and late weeks in development. Furthermore, COORS offers a valuable resource by providing novel markers linked to developmental states within MB, glioma, and DMG tumor subgroups. Conclusions Our work adds to our cumulative understanding of brain tumor heterogeneity and helps pave the way for tailored treatment strategies.
Year:
2025
Background World Health Organization Grade 2 meningiomas (G2Ms) often recur and resist therapies. Grade 2 meningiomas with histopathological necrosis have been associated with worse local control (LC) after radiation therapy, but the drivers and biomarkers of radiation resistance in G2Ms remain unknown. Methods We performed genetic sequencing and histopathological analysis of 113 G2Ms and investigated the role of genetic and microenvironmental factors on clonogenic survival after ionizing radiation. We performed transcriptional profiling of our in vitro model and 18 human G2M tumors by bulk RNA sequencing as well as 8 G2Ms by single nuclei RNA sequencing. Results NF2 loss-of-function (LOF) mutations were associated with necrosis in G2Ms (P = .0127). Tumors with NF2 mutation and necrosis had worse post-radiation LC compared to NF2 wildtype tumors without necrosis (P = .035). Under hypoxic conditions, NF2 knockdown increased radiation resistance in vitro (P < .001). Bulk RNA sequencing revealed NF2- and hypoxia-specific changes and a 50-gene set signature specific to radiation-resistant, NF2 knockdown, and hypoxic cells, which distinguished NF2 mutant/necrotic patient G2Ms by unsupervised clustering. Enrichment analysis revealed downregulation of apoptosis pathway genes and upregulation of proliferation-associated genes and genes normally downregulated after UV radiation exposure in NF2-mutant/necrotic tumor cells, which were validated with functional assays. Conclusions NF2 LOF in the setting of hypoxia confers radiation resistance through transcriptional programs that reduce apoptosis and promote proliferation. These pathways may identify tumors resistant to radiation and represent therapeutic targets that in the future could improve LC in patients with radiation resistant G2Ms.
Year:
2025
Year:
2025
Effective treatments for recurrent, radiation-relapsed meningiomas (RR-meningiomas) following surgery and radiation therapy (RT) are limited. Inhibitors of the programmed-death-1 (PD-1) or programmed-death ligand-1 (PD-L1) pathway have shown modest activity in single-arm phase II studies of RR-meningiomas. This study aimed to evaluate the immunological effects of combining avelumab, a PD-L1 inhibitory antibody, with proton beam therapy (PBT) in RR-meningiomas. Patients with grade 1-3 RR-meningiomas were treated with neoadjuvant avelumab plus hypofractionated PBT, followed by surgery and adjuvant avelumab. Correlative analyses included RNA-sequencing (RNA-seq), whole exome sequencing (WES), multiplex immunofluorescence (MxIF), single-nucleus RNA-seq (snRNA-seq) of pre- and post-treatment tumor tissues, and flow cytometry (FC) of serial blood samples. Nine patients were enrolled: three achieved an immunologic response and prolonged progression-free survival (PFS > 36 months). At a median follow-up of 47.2 months, the median PFS was 19.1 months (95% CI: 15.2-23.0). RNA-seq showed a dynamic change of tumor microenvironment (TME) signatures. MxIF revealed marked infiltration of T cells and CD68+CD206- (M1-phenotype) macrophages in the post-treatment tissues of responders, a pattern absent in non-responders, whose pre- and post-treatment tissues predominantly featured CD206+ (M2-phenotype) macrophages. These findings were supported by snRNA-seq, which identified FN1-associated immunosuppressive macrophage subtype enriched in non-responders. Additionally, FC revealed elevated peripheral primed T-cell signatures one-month after treatment initiation in responders, suggesting a potential predictive biomarker. Avelumab combined with RT may elicit an immune response in a subset of RR-meningiomas, leading to prolonged remission. Further investigations are warranted to validate these findings and to develop predictive biomarkers in larger prospective studies.
Year:
2025
Despite advances in brain tumor classification and molecular diagnostics, tools for early-stage, transcriptome-based prognostication remain limited, especially in low-resource settings. Polygenic prognostic models may better capture biological heterogeneity than single-gene approaches. We developed a fetal-to-adult index (FTAI), a transcriptomic score derived from normal human brain neurodevelopment, to enable biologically informed risk stratification across pediatric and adult brain tumors. Spatiotemporal transcriptomic data from the Allen Brain Atlas were used to curate fetal and adult gene sets, with 10-, 20-, and 30-gene panels tested via gene set variation analysis (GSVA). Principal component analysis confirmed clear separation by developmental stage. Using curated sets of genes highly expressed during fetal brain development (SOX2, PAX6, OLIG2, etc.) and genes with predominant expression in the adult brain (GFAP, S100B, SYN1, etc.) we confirmed developmental gene expression separation, with ~40% of variance explained by PCA (PC1). FTAI correlated strongly with chronological age—high in infancy and decreasing with age. FTAI was computed across 1,001 tumor samples, including pediatric brain tumors (PBTs, n=404), lower-grade gliomas (LGGs, n=522), and glioblastomas (GBMs, n=75), showing significant differences across groups (p=6.9x10-11). Higher FTAI was associated with worse overall survival in both PBTs and LGGs, as demonstrated by Kaplan–Meier survival analyses (PBTs: p<1.0x10-3; LGGs: p=1.2x10-2). In multivariable Cox and logistic models adjusted for age, sex, and race, each 0.1 increase in FTAI was associated with significantly worse prognosis (PBTs: HR 2.2 [p=1.5x10-3], aOR 2.8 [p=1.1x10-3]; LGGs: HR 1.86 [p=3.6x10-4], aOR 2.6 [p=1.4x10-3]), but not in GBMs (p>0.05). Machine learning models (random forest, XGBoost) using FTAI predicted survival with AUCs of 0.72. While post-hoc and sensitivity analyses revealed no significant association within individual pediatric tumor subtypes, likely due to limited sample sizes, this underscores its potential as a broadly applicable prognostic biomarker. Our findings support the FTAI as a static, polygenic, developmentally reflective index that enables early prognostic stratification across diverse brain tumor types, with applicability in both comprehensive and targeted transcriptomic workflows.
Year:
2025
Despite responses in other malignancies, immune checkpoint inhibitor immunotherapy does not significantly improve outcomes for most glioblastoma (GBM) patients. Our group previously showed that anti-PD-1 therapy extended survival in CD8-knockout (CD8-KO) mice, implicating that another immune population may mediate the therapeutic effect. Now, depleting the CD4 T-cell in the CD8-KO mice significantly extended survival (medOS=66) in syngeneic gliomas compared to CD8-WT mice treated with IgG (med OS=39.5, p-val=0.0256) or anti-CD4 alone (medOS=35.5, p-val=0.0008). Immune-enriched single-cell RNA sequencing from the gliomas during the therapeutic window (P45) revealed a previously underappreciated CD3⁺CD4⁻CD8⁻ double-negative T-cell (DNTs) population expanded in the tumor of the CD4-depleted CD8-KO mice. These DNTs exhibited upregulation of pro-inflammatory cytokines (Tnf, Ccl12), activation markers (Cd40lg, Il7r, Cd69, Cd226), and reduced expression of exhaustion markers (Pdcd1, Ctla4, Tox), distinguishing them transcriptionally from conventional T-cells. The DNT population lacks markers consistent with NK-cells, NK T-cells, or gamma-delta T-cells. In vitro, DNTs secrete TNF-α at baseline and in response to glioma stem cells (GSCs). DNT–GSC co-culture suppresses GSC proliferation by 20-36%. The DNTs co-cultured with M0 macrophages increased macrophage phagocytosis by 44%, as assessed by fluorescent E. coli uptake assays. Glioma-associated myeloid cells from DNT-enriched mice showed upregulated gene ontologies related to inflammation, antigen presentation, and phagocytic activation, contrasting with the immune tolerance signatures in the CD8-WT background mice. Moreover, anti-PD-1 treatment in the CD4-depleted CD8-WT background and the CD8-KO only mice blunted the survival difference, suggesting that global T-cell elimination is a prerequisite for the emergence of antitumor DNT function. In summary, our findings identify a novel immunoregulatory and antitumor role for DNTs in glioma, characterized by TNFα-driven inflammatory signaling and myeloid activation. These data uncover a previously unrecognized immune axis that may be leveraged to overcome immunotherapy resistance in GBM.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2022
Collaborators (15)
Guillermo Aldave
Baylor College of Medicine
Bhuvic Patel
Assistant Professor
Washington University in Saint Louis School of Medicine
David Bauer
Associate Professor
Texas Children's Hospital
Sameer Sheth
Baylor College of Medicine
Nisha Gadgil
Assistant Professor
Baylor College of Medicine
Ganesh Rao
Professor
Baylor College of Medicine
Junsung Woo
Assistant professor
Baylor College of Medicine
Benjamin Arenkiel
Associate Professor
Baylor College of Medicine
Benjamin Deneen
Associate Professor
Baylor College of Medicine
Kwanha Yu
Assistant Professor
Baylor College of Medicine
Namita Sinha
Shared Health Manitoba
Malcolm F. McDonald
The University of Texas MD Anderson Cancer Center
Melissa M. Blessing
Clinical Assistant Professor / Johnson County Deputy Medical Examiner
University of Iowa Hospitals and Clinics
Arif Harmanci
Assistant Professor
The University of Texas Health Science Center at Houston
Sungho Lee
Louisiana State University Health Sciences Center
Make your next move.
Prepare your application
Review drafts before you send them.